tyra biosciences is a biotechnology company targeting new pathways of acquired resistance in oncology with purpose-built drugs.
Company profile
Ticker
TYRA
Exchange
Website
Employees
Location
Fiscal year end
Industry (SIC)
SEC CIK
IRS number
831476348
TYRA stock data
Latest filings (excl ownership)
EFFECT
Notice of effectiveness
23 Apr 24
ARS
2023 FY
Annual report to shareholders
18 Apr 24
DEFA14A
Additional proxy soliciting materials
18 Apr 24
DEF 14A
Definitive proxy
18 Apr 24
PRE 14A
Preliminary proxy
5 Apr 24
S-8
Registration of securities for employees
19 Mar 24
S-3
Shelf registration
19 Mar 24
10-K
2023 FY
Annual report
19 Mar 24
8-K
Tyra Biosciences Reports Fourth Quarter and Full Year 2023 Financial Results and Highlights
19 Mar 24
D
Exempt offering of security
13 Feb 24
Latest ownership filings
Financial summary
Quarter (USD) | Sep 23 | Jun 23 | Mar 23 | Dec 22 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Annual (USD) | Dec 22 | Dec 21 | |
---|---|---|---|
Revenue | |||
Cost of revenue | |||
Operating income | |||
Operating margin | |||
Net income | |||
Net profit margin | |||
Cash on hand | |||
Change in cash | |||
Diluted EPS |
Cash burn rate (est.) | Burn method: Change in cash | Burn method: Operating income | Burn method: FCF (opex + capex) | Last Q | Avg 4Q | Last Q | Avg 4Q | Last Q | Avg 4Q |
---|---|---|---|---|---|---|
Cash on hand (at last report) | 216.65 mm | 216.65 mm | 216.65 mm | 216.65 mm | 216.65 mm | 216.65 mm |
Cash burn (monthly) | 5.59 mm | 3.96 mm | 7.99 mm | 5.78 mm | 5.72 mm | 4.05 mm |
Cash used (since last report) | 38.17 mm | 27.08 mm | 54.57 mm | 39.47 mm | 39.04 mm | 27.66 mm |
Cash remaining | 178.48 mm | 189.58 mm | 162.08 mm | 177.18 mm | 177.61 mm | 188.99 mm |
Runway (months of cash) | 31.9 | 47.8 | 20.3 | 30.7 | 31.1 | 46.7 |
Institutional ownership, Q3 2023
94.2% owned by funds/institutions
13F holders | Current |
---|---|
Total holders | 63 |
Opened positions | 5 |
Closed positions | 3 |
Increased positions | 16 |
Reduced positions | 16 |
13F shares | Current |
---|---|
Total value | 501.96 bn |
Total shares | 49.47 mm |
Total puts | 0.00 |
Total calls | 0.00 |
Total put/call ratio | – |
Largest owners | Shares | Value |
---|---|---|
Ra Capital Management | 7.24 mm | $99.65 bn |
Boxer Capital | 6.45 mm | $88.79 bn |
Canaan Partners XI | 4.41 mm | $60.73 bn |
Alta Partners NextGen Fund II Management | 4.08 mm | $81.24 mm |
Canaan XI | 3.94 mm | $55.39 mm |
FMR | 3.90 mm | $53.69 bn |
BVF | 2.74 mm | $37.72 bn |
Nextech Vi Oncology SCSP | 2.52 mm | $50.15 mm |
Nextech Invest | 2.52 mm | $34.68 bn |
Biotechnology Value Fund L P | 2.47 mm | $26.11 mm |
Recent insider trades
Date | Owner | Security | Transaction | Code | Indirect | 10b5-1 | $Price | #Shares | $Value | #Remaining |
---|---|---|---|---|---|---|---|---|---|---|
15 Mar 24 | Todd Harris | Common Stock | Grant | Acquire A | No | No | 6.579 | 1,880 | 12.37 k | 1,504,577 |
15 Mar 24 | Hiroomi Tada | Common Stock | Grant | Acquire A | No | No | 6.579 | 1,968 | 12.95 k | 86,435 |
15 Mar 24 | Fuhrman Alan | Common Stock | Grant | Acquire A | No | No | 12.478 | 932 | 11.63 k | 2,395 |
11 Mar 24 | Daniel Bensen | Common Stock | Sell | Dispose S | No | Yes | 20 | 200 | 4.00 k | 431,683 |
7 Mar 24 | Daniel Bensen | Common Stock | Sell | Dispose S | No | Yes | 20 | 68 | 1.36 k | 431,883 |
6 Mar 24 | Daniel Bensen | Common Stock | Sell | Dispose S | No | Yes | 20.092 | 1,733 | 34.82 k | 431,951 |
News
Wedbush Reiterates Outperform on Tyra Biosciences, Maintains $28 Price Target
21 Mar 24
Tyra Biosciences Q4 EPS $(0.53) Misses $(0.48) Estimate
19 Mar 24
S&P 500 Gains Over 1%; Amazon Earnings Top Expectations
2 Feb 24
Why Skechers Shares Are Trading Lower By Around 7%? Here Are Other Stocks Moving In Friday's Mid-Day Session
2 Feb 24
12 Health Care Stocks Moving In Friday's Intraday Session
2 Feb 24
Press releases
Tyra Biosciences to Present at Oppenheimer's 34th Annual Healthcare Life Sciences Conference
7 Feb 24
Tyra Biosciences, Inc. Announces $200 Million Private Placement Financing
2 Feb 24
Tyra Biosciences Receives FDA Rare Pediatric Disease Designation for TYRA-300 for the Treatment of Achondroplasia
1 Feb 24